161 related articles for article (PubMed ID: 32332473)
1. Successful Management of Methylphenidate or Atomoxetine-Related Priapism During Attention-Deficit Hyperactivity Disorder Treatment.
Karayagmurlu A; Coskun M
J Clin Psychopharmacol; 2020; 40(3):314-315. PubMed ID: 32332473
[No Abstract] [Full Text] [Related]
2. Priapism associated with the use of stimulant medications and atomoxetine for attention-deficit/hyperactivity disorder in children.
Eiland LS; Bell EA; Erramouspe J
Ann Pharmacother; 2014 Oct; 48(10):1350-5. PubMed ID: 24982313
[TBL] [Abstract][Full Text] [Related]
3. Priapism With Methylphenidate Use in a Preschool-Aged Boy Resolved With Switching to Atomoxetine.
Ekinci O; Üstündağ B; Tunali BD; Abdulrazzaq Al-Bayati MB; Demir H; Adak İ
Clin Neuropharmacol; 2019; 42(5):184-185. PubMed ID: 31361667
[TBL] [Abstract][Full Text] [Related]
4. Safety of Methylphenidate and Atomoxetine in Children with Attention-Deficit/Hyperactivity Disorder (ADHD): Data from the Italian National ADHD Registry.
Cortese S; Panei P; Arcieri R; Germinario EA; Capuano A; Margari L; Chiarotti F; Curatolo P
CNS Drugs; 2015; 29(10):865-77. PubMed ID: 26293742
[TBL] [Abstract][Full Text] [Related]
5. Methylphenidate-Associated Onychotillomania, Myoclonus, and Enuresis Reversed by Switching to Atomoxetine.
Naguy A; Alamiri B; El-Sori DS; Khraibut B
Am J Ther; 2019; 26(5):e614-e616. PubMed ID: 29927775
[No Abstract] [Full Text] [Related]
6. Adverse Drug Reactions Related to Mood and Emotion in Pediatric Patients Treated for Attention Deficit/Hyperactivity Disorder: A Comparative Analysis of the US Food and Drug Administration Adverse Event Reporting System Database.
Pozzi M; Carnovale C; Mazhar F; Peeters GGAM; Gentili M; Nobile M; Radice S; Clementi E
J Clin Psychopharmacol; 2019; 39(4):386-392. PubMed ID: 31205193
[TBL] [Abstract][Full Text] [Related]
7. ADHD update: new data on the risks of medication.
Harv Ment Health Lett; 2006 Oct; 23(4):3-5. PubMed ID: 17183739
[No Abstract] [Full Text] [Related]
8. Methylphenidate and atomoxetine treatment negatively affect physical growth indexes of school-age children and adolescents with attention-deficit/hyperactivity disorder.
Deng L; Zhou P; Zhu L; Zhang Y; Yang T; Zhao Q; Chen J; Li T; Cheng Q; Chen L
Pharmacol Biochem Behav; 2021 Sep; 208():173225. PubMed ID: 34217783
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular Safety of Atomoxetine and Methylphenidate in Patients With Attention-Deficit/Hyperactivity Disorder in Japan: A Self-Controlled Case Series Study.
Zheng Y; Fukasawa T; Yamaguchi F; Takeuchi M; Kawakami K
J Atten Disord; 2024 Feb; 28(4):439-450. PubMed ID: 38084080
[TBL] [Abstract][Full Text] [Related]
10. [Priapism - side effect of methylphenidate].
Aktuelle Urol; 2014 Mar; 45(2):94. PubMed ID: 24700059
[No Abstract] [Full Text] [Related]
11. The effects of medication on intraocular pressure in children with attention deficit hyperactivity disorder: A prospective study.
Guvenmez O; Cubuk M; Gunes S
J Popul Ther Clin Pharmacol; 2020 May; 27(2):e45-e50. PubMed ID: 32379404
[TBL] [Abstract][Full Text] [Related]
12. Methylphenidate-induced erections in a prepubertal child.
Kelly BD; Lundon DJ; McGuinness D; Brady CM
J Pediatr Urol; 2013 Feb; 9(1):e1-2. PubMed ID: 22552161
[TBL] [Abstract][Full Text] [Related]
13. Osmotic Release Oral System Methylphenidate Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder in Chinese Youth: 8-Week Comparative Efficacy and 1-Year Follow-Up.
Su Y; Yang L; Stein MA; Cao Q; Wang Y
J Child Adolesc Psychopharmacol; 2016 May; 26(4):362-71. PubMed ID: 26779845
[TBL] [Abstract][Full Text] [Related]
14. Long-Term Pharmacotherapy of Adults With Attention Deficit Hyperactivity Disorder: A Literature Review and Clinical Study.
Fredriksen M; Peleikis DE
Basic Clin Pharmacol Toxicol; 2016 Jan; 118(1):23-31. PubMed ID: 26404187
[TBL] [Abstract][Full Text] [Related]
15. Effects of Atomoxetine and Osmotic Release Oral System-Methylphenidate on Executive Functions in Patients with Combined Type Attention-Deficit/Hyperactivity Disorder.
Ince Tasdelen B; Karakaya E; Oztop DB
J Child Adolesc Psychopharmacol; 2015 Aug; 25(6):494-500. PubMed ID: 26218871
[TBL] [Abstract][Full Text] [Related]
16. Switch in Therapy from Methylphenidate to Atomoxetine in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: An Analysis of Patient Records.
Warrer P; Thomsen PH; Dalsgaard S; Hansen EH; Aagaard L; Wallach Kildemoes H; Rasmussen HB
J Child Adolesc Psychopharmacol; 2016 May; 26(4):354-61. PubMed ID: 26891424
[TBL] [Abstract][Full Text] [Related]
17. QTc prolongation after ADHD medication.
Snircova E; Marcincakova Husarova V; Ondrejka I; Hrtanek I; Farsky I; Nosalova G
Neuro Endocrinol Lett; 2018 Feb; 38(8):549-554. PubMed ID: 29504733
[TBL] [Abstract][Full Text] [Related]
18. Priapism associated with methylphenidate: a case report.
Cakin-Memik N; Yildiz O; Sişmanlar SG; Karakaya I; Ağaoğlu B
Turk J Pediatr; 2010; 52(4):430-4. PubMed ID: 21043394
[TBL] [Abstract][Full Text] [Related]
19. Combined methylphenidate and atomoxetine pharmacotherapy in attention deficit hyperactivity disorder.
Ozbaran B; Kose S; Yuzuguldu O; Atar B; Aydin C
World J Biol Psychiatry; 2015; 16(8):619-24. PubMed ID: 26223958
[TBL] [Abstract][Full Text] [Related]
20. Atomoxetine may improve methylphenidates' efficacy in treatment of ADHD?
Niederhofer H
Psychiatr Danub; 2009 Sep; 21(3):330. PubMed ID: 19794351
[No Abstract] [Full Text] [Related]
[Next] [New Search]
